New spray-dryer to handle 20kg batches, as Juniper responds to solubility demand

Image: iStock/garage131

Juniper Pharma Services will up its solubility enhancement capabilities through the addition of a new spray-dryer at its site in Nottingham, UK.

The contract development and manufacturing organisation has ordered a PSD-1 spray dryer from vendor GEA Niro as part of a series of continued investments at its clinical materials GMP-compliant manufacturing facility.

“It is generally understood that over 80% new chemical entities are poorly water soluble which means there are challenges in developing a viable formulation,” Juniper SVP Claire Madden-Smith told

“Spray drying is one of the technologies that can be used to help overcome this challenge and hence we are experiencing demand.”

Once installed later this year, the spray dryer will be able to handle batches of up to 20kg, allowing Juniper to provide customers with particle engineering options to address issues of solubility and bioavailability among clinical candidates.

The added dryer builds on Juniper’s bench-top scale spray drying equipment, but despite the scale-up Juniper will continue to focus on clinical materials and small-scale commercial production, Madden-Smith said.

“We are focused on providing pharmaceutical development services to navigate early development, where scale and capabilities align we will work with clients on their commercial manufacturing goals.”

The investment forms part of a wider investment programme at Juniper, she continued, hinting that there will be a significant step-up in the CDMO’s capabilities over the next year. The firm will also look to increase staff numbers at the site, she added.

“Juniper Pharma Services has and continues to increase its head count regularly, and whilst the PSD-1 will actually lead to operational efficiency we still anticipate our headcount increasing throughout the year.”

The investment comes weeks after fellow Nottingham-based CDMO Quotient Clinical announced it was expanding its spray-drying capacity. Meanwhile a number of other third-party manufacturers have invested in such technology, including Aesica, Pharmatek and Hovione.

Related News


Juniper invests in mixer tech for UK plant


Juniper invests in tablet technology for UK site

Image: The Eagle Blister Machine from MHI

'Americanizing' a Japanese blister machine

Image c/o Juniper Pharma Services

Roller compactor bolsters Juniper's granulation capabilities

Quotient Clinical acquisitions expanding US presence

Quotient Clinical acquisitions expanding US presence

Hovione produces active pharmaceutical ingredients (APIs) and conducts drug product intermediates development and manufacture. (Image: iStock/Delpixart)

Hovione launches first clinical trial, more to come

OxSonics has contracted Juniper to manufacture its tumour-targeting drug delivery aiding particles

Juniper to make OxSonics' ultrasound particles to aid cancer drug delivery

Image: iStock/keport

Juniper to reformulate unpleasant tasting PharmAust cancer drug

The Xceledose system: "similar to ‘tapping a pepper pot'" - photo Istock/AlonsoAguilar

'Drug-in-capsule' demand for trial material drives Juniper micro-dose investment

Juniper granted licence to make unlicensed medicines

MHRA licence to allow CDMO Juniper to manufacture 'Specials'

Donovan singing his hit Jennifer Juniper in 1968

What links gin, 1960s pop balladeer Donovan and Molecular Profiles?

Related Products

See more related products